Website intended for a NZ health professional readership
Dulaglutide has been funded for patients with type 2 diabetes since 1 September under Special Authority criteria. This case study summarises its potential benefits and risks, and how these should be considered when tailoring treatment to the individual
1. Goldenberg RM, Ahooja V, Clemens KK, et al. Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes. Can J Diabetes 2021;45(3):291–302.
2. Jabbour SA, Frías JP, Ahmed A, et al. Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: A multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 2020;43(10):2528–36.
3. Arnott C, Neuen BL, Heerspink HJL, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol 2020;318:126–29.
4. Díaz-Trastoy O, Villar-Taibo R, Sifontes-Dubón M, et al. GLP1 receptor agonist and SGLT2 inhibitor combination: An effective approach in real-world clinical practice. Clin Ther 2020;42(2):e1–12.
5. Guo M, Gu J, Teng F, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine 2020;67(2):294–304.
6. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–67.
7. Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2018;6(5):370–81.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
